The news: Eli Lilly filed six US lawsuits against sellers of black-market retatrutide, its obesity drug still in late-stage trials. It called on social media platforms, e-commerce marketplaces, credit card companies, payment processors, and shipping carriers to help curb illegal sales.

Lilly separately referred more than 200 individuals and entities to the FDA, Department of Justice, state attorneys general, and law enforcement. It has also reported over 14,000 websites, ads, social posts, and product listings marketing unapproved retatrutide across more than 100 countries.

Why this matters: The crackdown comes as retatrutide generates significant interest ahead of Lilly’s expected FDA submission next year. Retatrutide is Lilly’s next-generation weight loss medication that combines GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon peptide hormones, showing significant results of up to 30% weight loss in late-stage clinical trials, but is not legally allowed to be sold or marketed.

Unapproved retatrutide is being easily marketed to consumers online:

• Legendary Peptides lists a product simply called "Reta," priced from $75 to $210, labeling it "Research Use Only" alongside dozens of other peptides on its storefront.
• Astra Peptides advertises "Research-Grade Peptides, To Your Door" on its homepage and sells retatrutide under that same research-use framing.

"Research-use only" labeling doesn't make these sales legal. The FDA has warned products marketed that way are of unknown quality and pose risks when used for human purposes. Lilly says some sellers pose as legitimate medical providers while sourcing retatrutide from unregulated foreign manufacturers.

Implications for online healthcare companies and digital platforms: Lilly's public call-out broadens the focus from individual sellers to the infrastructure that enables them. Social platforms and marketplaces that host listings, and payment processors and carriers that facilitate transactions and shipping, now face direct reputational exposure tied to a named pharma company's enforcement campaign.

Companies could proactively curb retatrutide sales and the broader peptide market by removing black-market listings, blocking accounts, or cutting off payments could shrink retatrutide sales and stymie the broader peptide black market. That market uses similar “research-grade” language to sell celebrity- and influencer-touted peptides with limited clinical evidence or unresolved safety risks. If retatrutide is approved as expected next year, we expect Lilly’s aggressive policing to continue as compounders look to offer personalized versions, as they do with semaglutide and tirzepatide today.

Social media and digital platforms should treat this as a signal to audit peptide and similar unapproved drug promotions before a lawsuit or regulatory action forces a reactive response. Payment processors should review merchants tied to peptide retailers, as Lilly specifically called on credit card companies to help police illegal sales.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.